Home >
Publications/Products > HIV/Hepatitis C Coinfection Guidelines
for Health Care Providers
Table 7. Virologic Response Rates in the ACTG 5071 Study
Back to Management and Treatment of Hepatitis C Virus Infection in HIV-Infected Adults
| INF alfa-2a 6 MIU. tiw x 12 wk, then 3 MIU. tiw x 36 wk + RBV 600 mg increasing to 1,000 mg as tolerated over 6 wk | Peg INF alfa-2a (PEGASYS) 180 µg/wk x 48 wk + RBV 600 mg increasing to 1,000 mg as tolerated over 6 wk | |
|---|---|---|
| * p < 0.001 versus IFN + RBV; ** p = 0.03 versus IFN + RBV. | ||
| n = 67 | n = 66 | |
| ETR (Overall) | 12% | 41%* |
| Genotype 1 | 6% | 29% |
| Non-genotype 1 | 33% | 80% |
| SVR (Overall) | 12% | 27%** |
| Genotype 1 | 6% | 14% |
| Non-Genotype 1 | 33% | 73% |
From Management and Treatment of Hepatitis C Virus Infection in HIV-Infected Adults
Hepatitis C Resource Center Program and National Hepatitis C Program Office
September 2005
